Last reviewed · How we verify
CKD-314+SOC
CKD-314 is a selective PPAR-gamma agonist that enhances insulin sensitivity and glucose metabolism when combined with standard of care.
CKD-314 is a selective PPAR-gamma agonist that enhances insulin sensitivity and glucose metabolism when combined with standard of care. Used for Type 2 diabetes mellitus (as add-on to standard of care).
At a glance
| Generic name | CKD-314+SOC |
|---|---|
| Sponsor | Chong Kun Dang Pharmaceutical |
| Drug class | PPAR-gamma agonist |
| Target | PPAR-γ (Peroxisome proliferator-activated receptor gamma) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Diabetes |
| Phase | Phase 3 |
Mechanism of action
CKD-314 activates peroxisome proliferator-activated receptor gamma (PPAR-γ), a nuclear receptor that regulates genes involved in glucose homeostasis and insulin signaling. By enhancing insulin sensitivity in adipose tissue and skeletal muscle, it improves glycemic control. The '+SOC' designation indicates it is being evaluated as an add-on therapy to standard of care treatments in type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus (as add-on to standard of care)
Common side effects
- Weight gain
- Edema
- Hypoglycemia
- Heart failure exacerbation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CKD-314+SOC CI brief — competitive landscape report
- CKD-314+SOC updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI